Interleukin -2 ( IL -2 ) and interleukin -12 ( IL -12 ) are crucial cytokines that induce potent antitumor responses in a variety of animal cancer models. Although single gene transfer of either IL -2 or IL -12 exhibits limited antitumor effects, the combination of IL -2 and IL -12 has been shown to induce a stronger antitumor response and to cure tumor -bearing mice. To examine the conditions necessary for tumor rejection, we varied the local concentration of IL -2 and IL -12 by introducing these genes into Lewis lung carcinoma ( 
Interleukin -2 ( IL -2 ) and interleukin -12 ( IL -12 ) are crucial cytokines that induce potent antitumor responses in a variety of animal cancer models. Although single gene transfer of either IL -2 or IL -12 exhibits limited antitumor effects, the combination of IL -2 and IL -12 has been shown to induce a stronger antitumor response and to cure tumor -bearing mice. To examine the conditions necessary for tumor rejection, we varied the local concentration of IL -2 and IL -12 by introducing these genes into Lewis lung carcinoma ( LLC ) cells via retroviral vectors and / or an adenoviral vector and evaluated the growth of inoculated LLC cells ( 5Â10 A mong the various cancer gene therapies using a variety of genes with different gene transfer systems, immunogene therapy focuses on the use of genes for cytokines, chemokines, and costimulatory molecules. 1 ± 3 These approaches have successfully evoked antitumor responses in immmunocompetent animal models in vivo. Although it has been confirmed that immunomodulatory gene transfer into cancer cells or stromal cells activates the host immune responses through local production in the cancer tissue milieu, 4 ,5 the effect of any single immunogene transfer has been limited, especially against low immunogenic tumors. 6, 7 As the natural immune response against pathogenic infection consists of concerted and multicytokine responses, the potential usefulness of combined immunogene transfer should be explored toward the goal of obtaining adequate antitumor immune responses.
Interleukin-2 ( IL-2) and interleukin -12 (IL -12 ) are cytokines that elicit strong antitumor effects by stimulating immune cells including T cells and natural killer ( NK ) cells. Although either cytokine stimulates the proliferation of T cells, the production of interferon -(IFN -) by NK cells, and ultimately the cytolytic activity, 8 ± 10 the magnitude, and the spectrum of stimulatory effects by IL-2 and IL -12 are different. Although IL -2 is a stronger stimulator of proliferation and cytolytic activity, 11 ± 13 IL-12 is a stronger inducer of IFN -from NK cells and activated T cells. 14, 15 Importantly, IL -12 promotes the differentiation of naive CD4 + T cells into T helper type 1 ( Th1 ) cells. 16 ± 18 Although the combination of recombinant IL -2 and IL -12 treatment has been reported to be synergistic for inducing antitumor responses, 19 systemic administration of these cytokines causes toxic side effects. 20, 21 Although a recent report of intratumoral coinjection of an adenoviral vector expressing IL-2 and IL-12 demonstrated the regression of pre -established tumors with high frequency, 22 the significance of the amounts of IL-2 and IL -12 in the local milieu, in the context of mutual cytokine function, has not been addressed.
In the present study, we attempted to evaluate the relation between the amount of local cytokine production by the combination of IL-2 and IL -12 and the effective antitumor activity. Using low immunogenic Lewis lung carcinoma ( LLC ) cells, we transduced both IL -2 and IL -12 genes either by retroviral or adenoviral vectors, and monitored the IFN -production and CTL activity of spleen cells ( SPCs ) in treated mice. With the combination of constant but low IL -12 production by retroviral vectors and transient but high IL -2 production by adenoviral vectors, we observed the abolishment of LLC tumors in vivo.
MATERIALS AND METHODS

Tumor cell lines and mice
LLC cells and B16 murine melanoma cells were cultured in Eagle's minimum essential medium supplemented with 10% fetal bovine serum ( FBS ) . YAC -1 murine lymphoma cells and MCA 102 murine sarcoma cells were cultured in RPMI 1640 medium supplemented with 10% FBS. Male C57BL / 6 mice (5 weeks old ) were purchased from Japan Charles River ( Kanagawa, Japan ) .
Transduction of IL -2 or IL -12 cytokine gene into LLC cells by retroviral or adenoviral vector
The designated names of the LLC cells transduced with various cytokine genes as described below are summarized in Table 1 . A retroviral vector, TFG -m -IL -12 ( kindly provided by Dr. H Tahara, University of Pittsburgh School of Medicine, Pittsburgh, PA ), encodes both p35 and p40 murine IL -12 subunits with the IRES construct and selectable neomycin phosphotransferase gene under LTR control. 23 Another retroviral vector, PLXIN -m -IL -2, encoding murine IL-2 with selectable neomycin phosphotransferase gene under LTR control was constructed as follows. Murine IL -2 cDNA obtained from pmut -1 (ATCC 37533 ) was subcloned into the BamHI site of the retroviral vector, PLXIN (Clontech, Palo Alto, CA ), containing neomycin cDNA. Retroviral supernatants were generated using these proviral constructs and a ÉCRIP packaging cell line. 24 LLC cells (5Â10 5 /six -well dish ) were infected with these viral supernatants of the producer cell lines in the presence of polybrene (8 g/ mL ). As a negative control, a retroviral vector, PLXIN, carrying only the neomycin gene was used. Infected cells were subsequently selected by G418 (600 g /mL ), and G418 -resistant colonies were designated as LLC / TFGmIL -12, LLC /PLXINmIL -2, and LLC / neo. These cells were continuously cultured in bulk and used for the measurement of the in vitro cytokine expression and for the in vivo experiments. Secretion of mIL -2 and mIL -12 from these infected LLC cells was measured by enzymelinked immunosorbent assay ( ELISA kit, R&D Systems, Minneapolis, MN ).
The adenoviral vector, Adex -m -IL -2, encoding murine IL -2 (kindly provided by Dr. M Hamada, The Cancer Institute, Tokyo, Japan ) was propagated in 293 cells and the recombinant adenovirus was purified on cesium chloride gradients and stored at À 808C until use. LLC and LLC / TFGmIL -12 cells plated on dishes (1Â10 6 cells /10 cm diameter dish ) in Eagle's minimum essential medium with 2% FBS were infected with Adex -m -IL -2 at various multiplicities of infection ( MOI ) ( 10, 50, and 100 ) for 2 hours. The Adex -null carrying no cytokine gene was used as a control. These cells were designated as LLC /AdexmIL -2 and LLC /TFGmIL -12 /AdexmIL -2, respectively. Secretion of mIL -2 from these infected LLC cells was determined by ELISA kit (R&D Systems ) at 48 hours after adenoviral infection.
Tumor growth and vaccination in mice LLC cells ( 5Â10 5 /mouse ) transduced with various cytokine genes were inoculated subcutaneously ( s.c. ) into syngeneic C57BL /6 male mice, and tumors were measured with calipers in two perpendicular diameters every 2 or 3 days. Tumor volume was assessed as previously described. 25 For tumor growth evaluation, only mice that eventually developed tumors were considered. When mice inoculated with various gene-transduced LLC cells developed no tumors, the same number of parental LLC cells or MCA 102 cells was rechallenged at different sites from that of the initial inoculation at 4 weeks to evaluate for established protective immunity. The antitumor effect against preestablished LLC was also evaluated in two arms. In the first arm, parental LLC cells (5Â10 5 / mouse ) were inoculated in the right flank at day 0. At day 4, LLC /neo, LLC /TFGmIL-12, LLC / AdexmIL -2 ( 100 MOI), or LLC /TFGmIL -12 / AdexmIL -2 (100 MOI) cells were inoculated (5Â10 5 / mouse) in the left flanks of the mice. Tumor formation and size, when the cells formed tumors, were assessed every 2 or 3 days. In the second arm, parental LLC cells were inoculated in the same manner at day 0. When LLC tumors became palpable ( 2± 3 mm in diameter, day 10) , LLC / neo, LLC /TFGmIL -12, LLC /AdexmIL -2, or LLC / TFGmIL -12 /AdexmIL -2 cells were inoculated ( 5Â10 5 /mouse ) in the left flanks of the mice, and the tumor sizes were measured.
Immunohistochemical staining of tumors
For histological evaluation, tumors were harvested when they reached almost 1 cm in diameter. Tumor sections were embedded in Tissue-Tek OCT embedding medium ( Sakura Finetechnical, Tokyo, Japan ) and stored at À 808C until use. The cryostat sections were fixed in acetone at room temperature for 10 minutes, and then stained with various antibodies at 48C overnight. The primary antibodies used in the immunohistochemistry were rat monoclonal antibodies (MAbs) to the CD4 ( clone number: CT-CD4 ), CD8 (clone number: KT15 ) , dendritic /interdigitating cells (clone number: NLDC 145 ) (all from Serotec, Oxford, England ), and the anti -asialo GM1 polyclonal antibody (Wako, Tokyo, Japan ). The slides were stained with biotin -labeled second antibody, applied with ABC reagents ( Nichirei, Tokyo, Japan ) , and then counterstained by methylgreen for 1 minute. The number of immunostained cells was determined by light microscopy at Â100 magnification in five fields on a 1 -mm 2 grid and is given as number of cells per square millimeter ( mean SD ) .
IFN -production and CTL assay
SPCs obtained from mice at 7 or 14 days after tumor inoculation were cultured in 24 -well plates (1.2Â10 6 cells / well ) precoated with antimouse CD3 MAb (Pharmingen, San Diego, CA ) for 18 hours. IFN -production from SPCs was determined by ELISA kit ( Biosource International, Camarillo, CA ) .
Mononuclear cells were isolated from SPCs in mice transplanted with various LLCs by Lymphoprep (Nycomed Pharma, Oslo, Norway ) . These mononuclear cells were stimulated by irradiated (30 Gy ) LLC cells at an effector /target cells ratio of 10 in RPMI 1640 medium with 10% FBS for 5 days, and then viable lymphocytes were used as the effector cells.The cytotoxic assay was performed by standard 6 -hour 51 Cr-release assay. YAC -1 cells were used as target cells in the assay for NK activity, and B16 cells were used as allogeneic tumor cells.
Statistical analysis
The results were expressed as means SD and differences between them, except for the mice survival data, were analysis using two-tailed t test. The survival data in mice were calculated using Kaplan -Meier methods and were analyzed by the log -rank test. Statistical significance was defined as P <.05.
RESULTS
Semiquantitative evaluation of the secretion of IL -2 and IL -12 proteins using retroviral and adenoviral gene transduction
To assess the concentration of the immunomodulating cytokines, IL -2 and IL -12, in the local tumor milieu, different gene -transducing methods were applied to establish semiquantitatively the cytokine production from LLC Table 1 ) . Using Adex -m -IL -2 at a MOI of 100, the IL -2 production was 83.2 ng /10 6 cells/24 hours (between 24 and 48 hours after infection ), achieving 30 times higher production than that from LLC /PLXINmIL -2 cells. To assess the dual cytokine effect, LLC /TFGmIL -12 was infected with Adex -m -IL-2, which did not alter the individual secretion of IL -2 or IL-12 ( Table 1 ) . The cell growth in vitro and the morphology of these cytokine geneengineered LLC cells were not substantially different from those of LLC /neo and LLC cells. The data shown are the result of pools of two or three independent experiments.*MOI.yNumber of inoculated cells per mice.zMean SD. PLXINmIL -2 cells at day 21 was observed compared to LLC /neo cells, although all mice developed tumors ( Fig  1A ) . When we evaluated the effect of transient but high IL -2 secretion from LLC cells using Adex -m -IL -2 at increasing MOI, delayed tumor growth was observed in accordance with the MOI of the adenoviral vector ( Fig  1B ) despite the fact that tumors developed in almost all mice inoculated (Table 2 ) . (Fig 2) . Increasing the cell number up to 10 6 cells each did not enhance the tumor suppression (data not shown) .
In contrast, when the adenoviral vector encoding the mIL -2 gene was transduced to LLC /TFGmIL -12 cells, the host immune response was potentiated to reject the LLC tumor formation regardless of the comparable IL -12 production ( Fig 2 ) . In this regard, LLC /TFGmIL -12 cells were infected with Adex -m -IL -2 at a MOI of 100 in vitro, and 5Â10 5 cells thus prepared were s.c. inoculated into the left flanks of syngeneic C57BL /6 mice. Tumors did not form in 9 of 12 mice challenged (Table 2 ) . Furthermore, the tumors that developed in three mice did not grow progressively until 3 weeks (Fig 2 ) . Neither LLC /TFGmIL -12 cells infected with the null adenoviral vector at a MOI of 100, nor LLC / TFGmIL -12 cells infected with Adex -m -IL -2 at a MOI of 10 or 50 demonstrated an abrogation of tumor establishment, indicating the dependency of IL -2 and its local concentration.
Survival curves and rechallenge trial of mice transplanted with gene -transduced LLC cells
All mice transplanted with LLC / neo, LLC /TFGmIL-12, or a mixture of LLC /TFGmIL-12 and LLC /PLXINmIL -2 (Fig 3) . Although single gene transduction of either IL -2 or IL -12 decreased the tumor growth significantly, only IL -2 gene transfer by the adenoviral vector yielded a significant survival benefit compared to control LLC cells (P < .05) . In contrast, mice transplanted with LLC /TFGmIL -12 /AdexmIL -2 cells (100 MOI ) lived significantly longer than those with only the control vector or single gene transfer (P < .01) . LLC / TFGmIL-12/ AdexmIL -2 (100 MOI) cells developed tumors in only 3 of 12 mice transplanted, and the other nine mice were tumor-free until 70 days. In a separate experiment, when tumor-free mice (eight mice) at 4 weeks after LLC / TFGmIL -12 /AdexmIL -2 inoculation were rechallenged with parental LLC cells (5Â10 5 /mouse) , tumor formation was rejected in five of eight mice during the 60 -day observation period. During this period, the initial inoculation sites did not develop tumors. In contrast, when tumorfree mice (seven mice ) were rechallenged with MCA 102 murine sarcoma cells ( 5Â10 5 /mouse ), all of them formed tumors within 9 days that grew as fast as in nontreated C57BL /6 mice.
Antitumor effect against pre -established LLC tumors
In the next step, we examined whether the vaccination of LLC /TFGmIL -12 /AdexmIL -2 cells exerts antitumor effects against pre -established parental LLC tumors. Consistent with the previous experiment, LLC tumors were eventually formed in mice vaccinated with LLC / TFGmIL -12 alone or LLC /AdexmIL -2 alone. However, three of eight mice vaccinated with LLC / TFGmIL -12/ AdexmIL -2 did not develop LLC tumors in the first arm during the 60 -day observation. The tumor growth of parental LLC in mice vaccinated with LLC /TFGmIL -12 alone or LLC /AdexmIL -2 alone was slower compared with mice vaccinated with control LLC /neo cells, but the difference was not statistically significant (Fig 4 ) . The growth of parental LLC tumors of mice vaccinated with LLC /TFGmIL -12 /AdexmIL -2 was significantly suppressed compared with that of control tumors by 28% ( P <.05 ). Vaccination with any of the gene -transduced LLC cells administered after the parental LLC tumor became palpable in the second arm, however, showed no tumor regressive effect (data not shown) .
Infiltration of immune effector cells into tumors of various cytokine gene -transduced LLC cells
When immunohistochemical staining of LLC tumors was performed to examine the underlying host immune reaction in the tumors with various cytokine gene transfers, considerable differences in both the numbers and combinations of the immune effector cells, CD4 + T lymphocytes, CD8 + T lymphocytes, NK cells, and dendritic cells ( DCs ) were observed. Whereas moderate amounts of CD4 + T lymphocytes but not CD8 + T lymphocytes infiltrated into LLC /AdexmIL -2 tumors, massive amounts of CD8 + T lymphocytes and moderate amounts of CD4 + T lymphocytes infiltrated into LLC /TFGmIL -12 tumors ( Fig 5,  Table 3 ) . In contrast to single gene-engineered tumors, both CD4 + and CD8 + T lymphocytes extensively infiltrated into LLC /TFGmIL -12 /AdexmIL -2 tumors ( Fig 5) . It was also noted that there was a low but constant number of NK cells and DCs in tumors with IL-12 production, but not in tumors with only IL-2 production ( Table 3) . These immune effector cells were predominantly found in the peripheral area of the tumor (Fig 5) .
Functional analysis of SPCs from mice transplanted with single or dual cytokine gene -transduced LLC cells
Because IL -2 and IL -12 are reported to show antitumor effects through the induction of IFN -from T lymphocytes, IFN -production from SPCs in mice transplanted with gene -engineered LLC cells was evaluated (Fig 6) . Although SPCs in mice transplanted with LLC /TFGmIL-12 produced larger amounts of IFN -(22.0 3.2 pg/mL at day 7 ) than those with LLC / neo (7.93 2.50 pg /mL ) , SPCs with LLC /AdexmIL -2 secreted even larger amounts of IFN -( 34.8 5.5 pg/ mL ) . However, no additive or synergistic stimulation of IFN -production was observed in SPCs with LLC /TFGmIL-12 /AdexmIL -2 ( 39.5 7.7 pg /mL ). In contrast to SPCs with LLC /TFGmIL -12, SPCs at day 14 with LLC / AdexmIL -2 or LLC / TFGmIL -12/ AdexmIL -2 secreted equal amounts of IFN -compared to those at day 7 (37.3 7.1 or 32.6 4.3 pg/ mL ) . Furthermore, despite the comparable IFN -production from SPCs, cytotoxic activity was detected only in SPCs from mice showing rejection of LLC /TFGmIL -12 /AdexmIL -2 cells (Fig 7 ) . In this context, SPCs from mice with LLC / TFGmIL -12 /AdexmIL -2 showed significant cytotoxicity against parental LLC cells ( 39.9% cytolytic activity at an E /T ratio of 50) but not against B16 or YAC -1 cells, indicating that this cytotoxicity was specific for LLC cells and the presence of memory cells.
DISCUSSION
The rejection or growth of inoculated cancer cells in immunocompetent mice represents a complicated balancing matter. Among the considerable number of reports describing potentiated antitumor immunity by the use of the major cytokines IL -2 and IL -12, our report is unique in that a semiquantitative evaluation of these cytokines was performed in the border between tumor suppression and tumor rejection. In the current study, we prepared a variety of IL -2± and/ or IL -12 ± transduced LLC cells using retroviral vectors and an adenoviral vector. We first tried a stepwise evaluation of the effect of single cytokine production in LLC cells. Using IL -2 ± transduced LLCs ( IL-2 production ranging from 2.8 to 83.2 4.7 ng /10 6 cells /24 hours ) , tumor formation regressed for several days, but insufficient tumor rejection was observed against LLCs; only one mouse inoculated with LLC /AdexmIL -2 (100 MOI) (5Â10 5 cells ) rejected the LLCs. Using IL -12 ±transduced LLCs ( 9.6 ng /10 6 cells/ 24 hours ), all tumors were suppressed but not rejected. It is of interest that, whereas comparable amounts of IL -12 production from cloned IL -12 ± transduced LLCs had successfully elicited tumor rejection, 7 bulk IL -12 production from LLC /TFGmIL -12 did not achieve the same effect, although such treatment would be clinically practical. In this context, when we compare the available reports on the production of IL -12 from transduced cancer cells in regard to tumor rejection (Table 4 ) , a minimal amount of IL -12 production is likely to be required against a fixed number of cells inoculated for tumor rejection.
In an attempt to study the combinatory effect of IL -2 and IL -12, we again planned a stepwise evaluation of cytokine production. Whereas the combination of retroviral -transduced LLC / PLXINmIL -2 and LLC / TFGmIL -12 showed only a negligible effect for both the suppression and rejection of the inoculated cells, the unique dual transduction of LLC /TFGmIL -12 /AdexmIL -2 (100 MOI) ( IL -12; 4.6 ng/5Â10 5 cells / 24 hours, IL -2; 42.5 ng /5Â10 5 cells /24 hours for transient production ) finally elicited a host immune response for the rejection of LLCs in 75% of the mice, indicating that the local IL-2 and IL -12 concentration in this experimental condition was at a critical threshold for evoking a coordinated host immune effector function. It should be noted that the combination of IL-2 and IL -12 production exerted a synergistic effect because the production of IL -12 in the dual -transduced LLCs was at the same level that caused only a negligible response when used alone.
Among the mice that rejected LLCs, the rechallenge of parental LLCs (5Â10 5 cells ) at 4 weeks resulted in rejection in five of eight mice (63% ), demonstrating the establishment of memory T cells in the responder mice. In the analysis of the lymphocytes using MAbs in the tumors consisting of LLC /neo, LLC /TFGmIL -12, LLC / AdexmIL -2, and LLC /TFGmIL -12 /AdexmIL -2, significant differences in the numbers of CD4 + T cells and CD8 + T cells were noted ( Although potent antitumor immunity is attributed to the secretion of IFN -from T cells activated by IL -12, the IFNproduction from SPCs in our system was comparable in LLC /TFGmIL -12 ( 22.0 3.2 pg /mL ) and in LLC / TFGmIL -12/AdexmIL -2 ( 39.5 7.7 pg/ mL ) (Fig 6) , indicating that additional factors other than IFN -, though indispensable, are required for the rejection. When SPCs from mice with various inoculated LLCs were assessed for the induced killing activity against parental LLCs, only SPCs from mice with LLC /TFGmIL -12 /AdexmIL -2 showed LLC -specific cytotoxicity (Fig 7 ) , indicating the existence of protective antitumor immunity.
Our result suggests that dual transduction of IL -2 and IL -12 into LLCs synergistically elicited a host antitumor response causing the rejection of parental LLCs. Among the established cancer cell lines used in mouse experimental models, LLC is known as one of the low antigenic cancer cell lines. In our previous report, 28 we demonstrated that IL -12 exerts its function on cancer cells by augmenting MHC class I expression in addition to its major function on T cells. Although Sumimoto et al 7 showed that a clone of retroviral transduced IL -12 into LLC evoked a potent immune rejection response, they also described that an in vitro killing assay induced both tumor-specific and some nonspecific killing activity. In contrast, we demonstrated LLC -specific killing only from mice with dual IL-2± and IL -12 ± transduced LLCs. The absence of CTL activity in mice with either IL -2 ± or IL -12± transduced LLC may reflect the poor immunogenicity of LLC and other antitumor mechanisms.
Furthermore, the combined use of these cytokines induces a synergistic function, thus reducing adverse effects such as those described in a clinical trial of rIL -2 20 and also in one involving rIL -12. 21 In this regard, by using tumor cells producing two cytokines such as IL -2 and IL -4 6 or IL -2 and IL-6, 29 strong antitumor immunity could be induced compared to cells with either one alone. By using retroviral vectors encoding IL -2 and IFN -, successful antitumor immunity has been obtained. 30 As for IL -2 and IL -12 in combination, Addison et al 22 demonstrated the induction of a potent antitumor response by in vivo intratumoral injection of IL -2 and IL -12 expression adenoviral vectors. In their model, increased regression of untreated distal tumors by circulating CTLs was remarkable, though 10% of the mice died, probably because of the adverse effects of high IL -2 and IL -12 production. 31 Another report studied the combined effect of IL -2 ± and IL -12 ±transduced fibroblasts using retroviral vectors in a murine melanoma model. In agreement with our result, the antitumor effect with the combination of IL -2 and IL -12 by retroviral vectors was not superior to IL -2 alone. 32 In our system, we utilized the adenoviral vector only for higher IL -2 production and obtained fairly comparable rejection rates without fatal effects. In this regard, Lode et al 33 reported that the T cell ±mediated immune response induced by IL -12 gene therapy was also amplified using tumor-targeted IL -2. For future investigations, the appropriate way to introduce combinations of cytokines should be addressed.
CONCLUSION
This study demonstrated a synergistic antitumor response by combined immunogene therapy of IL -2 and IL -12 in low antigenic LLC. Analysis of infiltrating lymphocytes in the tumor and in vitro killing suggested the importance of CD4 + T cells in addition to CD8 + CTLs.
